Tryptase is a protein released primarily by mast cells, a type of immune cell found in skin, airways, and the gut, and elevated levels in the blood point to one of several possibilities: an acute allergic reaction, an underlying mast cell disorder, a genetic trait that raises levels from birth, or sometimes a condition that has nothing to do with mast cells at all. A single tryptase reading on its own rarely tells the whole story. What matters is the context: whether the level spiked suddenly during an event, sits persistently above normal at baseline, or both.
What Tryptase Actually Does
Tryptase is the most abundant substance stored inside mast cell granules. When mast cells activate and dump their contents, tryptase floods into surrounding tissue and eventually into the bloodstream. It belongs to a family of enzymes that cut other proteins, and it plays roles in inflammation, airway function, blood vessel tone, and gut motility.1PubMed. Mast cell tryptase: a review of its physiology and clinical significance Think of mast cells as alarm systems scattered throughout your tissues; tryptase is the loudest siren they set off.
There are different forms of tryptase, and this matters clinically. Beta-tryptase is the enzymatically active form, the one that does most of the biological work. Alpha-tryptase, by contrast, lacks a critical structural feature at its active site and has almost no enzymatic activity.2PubMed Central. Inherited and acquired determinants of serum tryptase levels in humans The distinction matters because most of the tryptase circulating in your blood at rest is actually the inactive “pro” form, while the active beta-tryptase surges during an allergic event. Standard blood tests measure total tryptase, which captures both forms together.
Acute Spikes During Allergic Reactions
The most dramatic reason tryptase shoots up is anaphylaxis. During a severe allergic reaction, mast cells throughout the body degranulate all at once, dumping beta-tryptase into the bloodstream. Tryptase typically peaks within one to two hours of symptom onset and returns toward baseline within several hours, which is why emergency departments try to draw blood quickly after a suspected anaphylactic event.
But here is where interpretation gets tricky. A tryptase level of, say, 14 ng/mL during an acute event might look elevated compared to the usual reference range, yet it could be perfectly normal for someone whose baseline tryptase already sits at 12. To solve this problem, an international consensus group developed what is called the “20% + 2” formula: the acute tryptase value should exceed 1.2 times the person’s baseline plus 2 ng/mL to confirm that genuine mast cell activation occurred.3PubMed. Validation of international consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective This formula has been validated by independent clinical groups and is now considered a diagnostic standard for confirming mast cell activation during an acute event.4PubMed Central. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome
The practical takeaway: if you are being evaluated for a suspected anaphylactic episode, your doctor ideally needs two blood draws, one during or shortly after the event and one at least 24 hours later when you are back to your usual state. Without a baseline to compare against, a single measurement can be misleading in either direction.
Persistently Elevated Baseline Tryptase and Mastocytosis
When tryptase stays elevated at rest, without any acute allergic event driving it up, the clinical picture changes. A persistently high baseline, particularly above 20 ng/mL, raises concern for systemic mastocytosis, a condition in which abnormal mast cells accumulate in bone marrow and sometimes in skin, liver, or spleen. Elevated baseline tryptase is one of the minor diagnostic criteria for systemic mastocytosis, alongside markers like abnormal mast cell surface proteins and the presence of an activating mutation in the KIT gene.5PubMed Central. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal Other minor criteria include expression of certain markers on mast cells and the KIT D816V mutation.6PubMed. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management
In mastocytosis, the tryptase level does more than just flag the diagnosis. It roughly tracks how much disease is present. Studies have shown that the burden of the KIT D816V mutation correlates with serum tryptase, meaning higher tryptase generally reflects a larger population of abnormal mast cells.7PubMed. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis That said, tryptase and mutation burden measure slightly different things: tryptase reflects the load of mature mast cells specifically, while the mutation can be present in other cell types as well.8PubMed Central. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease Rising tryptase over time in a patient with known mastocytosis is therefore a signal that warrants closer monitoring.
Hereditary Alpha-Tryptasemia
Not everyone with a chronically high tryptase level has a mast cell disease. Hereditary alpha-tryptasemia, or HαT, is a genetic trait in which a person carries extra copies of the gene encoding alpha-tryptase. It is inherited in an autosomal dominant pattern, meaning you only need one copy from one parent to have the trait.9PubMed Central. Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features The extra gene copies lead to higher production of alpha-tryptase, which pushes the total tryptase reading up even though the person’s mast cells are functioning normally. Updated consensus criteria for mastocytosis explicitly acknowledge that HαT is one of the conditions that can cause tryptase elevations above 20 ng/mL without mastocytosis being present.5PubMed Central. Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
For years, HαT was thought to be a benign curiosity. Newer research suggests it is more nuanced. In one allergy center cohort, patients with HαT reported a significantly higher overall symptom burden compared to those without the trait. The difference was not limited to classic allergic complaints: people with HαT were more likely to report fatigue, sleep disturbances, concentration issues, headaches, abdominal pain, palpitations, and dizziness.10PubMed Central. Extended multisystem manifestations of hereditary α-tryptasemia in an allergy center cohort Research into how extra alpha-tryptase gene copies affect gut function and immune responses is ongoing, and HαT may turn out to be clinically relevant beyond simply inflating a lab number.11PubMed Central. Hereditary α-tryptasemia; a review of mechanisms linking α-tryptase gene dosage to intestinal homeostasis and immunopathology
The prevalence of HαT is estimated at roughly 4 to 6 percent in western populations, which makes it surprisingly common. If you have a chronically elevated tryptase and your doctor cannot find evidence of mastocytosis or another mast cell disorder, genetic testing for HαT is a reasonable next step.
Mast Cell Activation Syndrome
Mast cell activation syndrome, or MCAS, sits in a different category from mastocytosis. In mastocytosis, the problem is too many mast cells. In MCAS, the total number of mast cells is normal, but they are functionally overactive, releasing mediators when they should not.12PubMed Central. The Curious Case of Elevated Tryptase: Workup and Differential in Family of Four MCAS produces episodic symptoms, typically involving more than one organ system, such as flushing, hives, cramping, diarrhea, lightheadedness, and sometimes full anaphylaxis.
Diagnosing MCAS requires meeting three criteria at once: acute symptoms consistent with mast cell activation affecting multiple organ systems, an event-related rise in tryptase that meets the 20% + 2 formula compared to the person’s own baseline, and a clinical response to medications that target mast cell mediators.13PubMed Central. Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders An important caveat: a chronically elevated baseline tryptase alone does not prove MCAS, nor does a normal baseline rule it out.14PubMed Central. Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach MCAS is defined by the pattern of episodic activation, not by the resting tryptase number.
This distinction trips people up frequently. Online communities sometimes treat any elevated tryptase as synonymous with MCAS, but the diagnostic criteria are specific and require documentation of an acute rise during a symptomatic episode. A single resting blood draw showing a level of, say, 15 ng/mL does not meet that standard on its own.
Causes Outside Mast Cell Disorders
Several conditions can push tryptase up without any mast cell pathology at all. These are sometimes called “secondary” causes, and missing them can lead to unnecessary worry or invasive workups.
Kidney disease is one of the more common non-mast cell causes. In patients with advanced chronic kidney disease and those on dialysis, tryptase levels are often roughly double those seen in early-stage kidney disease. One study found average tryptase levels around 13 to 15 µg/L in advanced kidney disease, compared with about 7 µg/L in milder stages.15PubMed. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease The mechanism is not straightforward. Tryptase is not actually filtered into the urine, so the kidneys do not clear it that way.16PubMed Central. Tryptase is not cleared by the kidneys into the urine The elevation may instead reflect chronic inflammation and possibly altered metabolism of tryptase in the setting of kidney failure.17PubMed Central. Serum baseline tryptase levels across chronic kidney disease stages: A retrospective report
Blood cancers of the myeloid type can also cause elevated tryptase. The elevations cluster specifically in myeloid neoplasms rather than lymphoid ones. Among myeloid conditions, over 90 percent of systemic mastocytosis patients showed tryptase above 15 ng/mL (expected, since mastocytosis is itself a myeloid disorder), but elevated readings were also found in roughly a third of patients with acute myeloid leukemia or chronic myeloid leukemia and about a quarter of those with myelodysplastic syndromes.18PubMed. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology This makes tryptase a potentially useful screening marker in hematology, flagging patients who may warrant closer evaluation for myeloid disease.19PubMed Central. The serum tryptase test: an emerging robust biomarker in clinical hematology
Acute heart attacks have also been associated with modest tryptase elevations. A preliminary study found that patients experiencing a type of heart attack involving complete blockage of a coronary artery had roughly double the tryptase levels of healthy volunteers, likely reflecting mast cell activation within unstable coronary plaques.20PubMed Central. Elevated Serum Tryptase and Endothelin in Patients with ST Segment Elevation Myocardial Infarction: Preliminary Report This area of research is still early, and tryptase is not used in cardiac diagnostics today, but it illustrates how mast cells participate in processes far beyond classic allergy.
Baseline Tryptase as a Risk Factor for Severe Allergic Reactions
Even when a baseline tryptase level falls within the normal reference range, its position within that range carries information. People with higher resting tryptase, even values well below 20 ng/mL, face a greater risk of severe anaphylaxis when exposed to a trigger. This has been studied most thoroughly in people allergic to bee and wasp stings. A European study found that the frequency of severe systemic reactions increased significantly with higher baseline tryptase, and the relationship was not a simple straight line but followed a curve that steepened at higher values.21PubMed. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity For allergists managing patients with venom allergy, baseline tryptase is one of the strongest predictors of who is at risk for life-threatening reactions.22PubMed Central. Diagnostic measures in patients with severe insect sting reactions and elevated baseline serum tryptase levels
This is why some specialists now recommend checking baseline tryptase in anyone who has experienced unexplained anaphylaxis or a severe allergic reaction to an insect sting, even if they seem otherwise healthy. A higher-than-average baseline may change decisions about the duration of venom immunotherapy or whether to prescribe additional epinephrine auto-injectors.
Practical Aspects of Testing
One advantage of tryptase testing is that the protein is remarkably stable once drawn. Unlike many blood biomarkers that degrade quickly, tryptase samples can sit at room temperature for at least 24 hours without meaningful loss of accuracy. The test is also unaffected by hemolysis, the accidental breakage of red blood cells during a blood draw that ruins many other lab tests.23Journal of Allergy and Clinical Immunology. What Causes High Tryptase Levels & What Do They Mean? These features mean that even hospitals without an on-site tryptase assay can ship samples to a reference lab and still get reliable results.
Timing, however, is critical for acute measurements. For anaphylaxis, the blood draw should happen within four hours of symptom onset. Tryptase peaks and then falls, so drawing too late can yield a falsely normal result and obscure an event that genuinely involved mast cell activation. A baseline sample should be drawn at least 24 hours after complete recovery. In practice, this means the baseline is often obtained at a follow-up visit rather than in the emergency department.
What Tryptase Does to Tissues Over Time
Beyond its diagnostic value, tryptase is not just a passive marker floating in the blood. Active beta-tryptase drives biological processes that can cause chronic tissue damage. One of its key actions is activating a receptor called PAR-2 on the surface of various cell types. In the lungs, tryptase-driven PAR-2 activation promotes the migration of fibroblasts, the cells responsible for laying down scar tissue, which may contribute to airway remodeling in chronic lung diseases.24PubMed Central. Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2 The same PAR-2 pathway has been implicated in fibrosis of other organs. Recent research demonstrated that mast cell tryptase drives collagen production in ovarian tissue through PAR-2 signaling, and blocking either PAR-2 or certain downstream molecules reduced that collagen buildup.25PubMed Central. Mast cell tryptase-PAR2 axis promotes ovarian fibrosis through RNF152-mediated stabilization of Bcl-xL
These findings help explain why conditions involving chronic mast cell activation can produce such a wide range of organ-level damage over time. The tryptase itself is not an innocent bystander; it is actively reshaping the tissue it contacts.
Experimental Therapies That Target Tryptase Directly
Because tryptase contributes to tissue damage in asthma, allergy, and fibrotic disease, pharmaceutical researchers have been trying to neutralize it. Active beta-tryptase works as a cluster of four protein subunits locked together. One therapeutic approach involves an antibody that binds to tryptase and forces those four subunits apart, converting an active enzyme into inactive fragments. Early-phase work produced a humanized antibody that successfully inhibits both alpha- and beta-tryptase forms.26PubMed Central. An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma A related antibody called MTPS9579A was tested in healthy volunteers and shown to inactivate airway tryptase in a dose-dependent fashion by the same tetramer-dissociation mechanism.27PubMed Central. Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial
More recent work has gone a step further, developing an antibody that not only breaks apart the tetramer but also inhibits the leftover single subunits, which retain some enzymatic activity on their own.28PubMed Central. Complete inhibition of β-tryptase by tetramer dissociation and active site allostery due to a single antibody residue None of these agents are approved treatments yet, and clinical trials in disease populations are still underway. But the strategy represents a fundamentally different approach from current mast cell therapies, which mostly block the effects of histamine and other mediators after release. Targeting tryptase directly would neutralize one of the most potent enzymes mast cells deploy, potentially reducing the downstream tissue damage that existing drugs leave unaddressed.